Sign inJoin waitlistJoin the waitlist

Melinda Pauly

Overall Medical Director of Aflac and Medical Director of Oncology · Emory University School of Medicine

Credentials: · ·

History

Aflac and Medical Director of Oncology · Emory University School of Medicine
Present
Aflac Cancer and Blood Disorders Center · Emory University School of Medicine
Present
Emory University School of Medicine
Present

Pediatric Hematology/Oncology
Emory University School of Medicine
2010–2013
Pediatrics
The University of Alabama
2007–2010
Emory University School of Medicine
2003–2007

Research

Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment
Nature · 2016 · 211 citations
Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R
British Journal of Haematology · 2017 · 116 citations
Single-cell analysis reveals altered tumor microenvironments of relapse- and remission-associated pediatric acute myeloid leukemia
Nature Communications · 2023 · 59 citations

Lia Gore
5 papers
Eric Schafer
4 papers
HS
Himalee Sabnis
4 papers
Mignon Loh
4 papers
Alan Wayne
3 papers
Andrew Place
3 papers
BC
Bill Chang
3 papers
Daniel Wechsler
3 papers · 1 as a fellow
Deepa Bhojwani
3 papers
FK
Frank Keller
3 papers
GL
Glen Lew
3 papers
Lewis Silverman
3 papers

Clinical trials

Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia
Principal investigator · Withdrawn · Phase 1
Emory University
2015–2017
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Site PI · Recruiting · Phase 1
Therapeutic Advances in Childhood Leukemia Consortium
2022–2027
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Site PI · Recruiting · Phase 2
Etan Orgel
2022–2032